Dr Reddy's Laboratories Q1 Results Preview: Profit May Fall 40%, EBITDA Seen Down 35%; US Business in Focus

Dr Reddy's Laboratories is set to announce its financial results for the quarter ended June 30, 2026 (Q1 FY27) on July 22, with analysts expecting earnings to remain under pressure despite stable business momentum in some markets. Investors will closely watch the pharmaceutical major's performance, particularly its North American business, which continues to face pricing challenges.

Dr Reddy's Laboratories Q1 Results Announcement Today: What To Expect

Brokerage estimates suggest both operating profit and net profit could decline compared with the same period last year, mainly due to lower contribution from key products and intense competition in the US generics market.

Dr Reddy's Q1 Results Preview: Net Profit, EBITDA Expected to Decline

Market estimates indicate that EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) could fall by nearly 35% year-on-year, while net profit may decline by around 40% during the June quarter as per Businessline report.

Although revenue is expected to remain relatively stable, weaker profitability is likely to weigh on the company's overall financial performance. Analysts believe the quarter could reflect continued pressure on margins rather than a significant slowdown in sales.

US Business Likely to Remain the Biggest Challenge

The performance of Dr Reddy's North American business is expected to remain the biggest focus area in the upcoming results.

The US contributes a significant share of the company's earnings, but the market has become increasingly competitive as more companies launch generic versions of the same medicines. Greater competition typically leads to lower selling prices, making it difficult for drugmakers to maintain profit margins.

Analysts also expect lower revenue from generic Revlimid, a product that had supported earnings in previous quarters. As competition increases, the contribution from the drug is expected to moderate, putting additional pressure on profitability.

Margins to Remain Under Pressure Despite Stable Revenue

While the company's overall revenue may not witness a sharp decline, investors are expected to focus more on profitability indicators such as gross margins and EBITDA margins.

Lower pricing in the US market, a weaker product mix and reduced contribution from high-margin products could impact operating margins during the quarter.

Market participants will therefore closely analyse whether the company has been able to offset some of these pressures through cost efficiencies or improved performance in other businesses.

Apart from the quarterly numbers, investors will pay close attention to management's outlook for the coming quarters. Updates on upcoming product launches, regulatory approvals, complex generics, biosimilars and the overall demand environment in the US market could provide important clues about future earnings growth.

Management's commentary on pricing trends in North America and the company's strategy to strengthen margins will also remain key triggers for the stock.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.